Management Team
Tom Eisiminger, Jr. – President and Chief Executive Officer
Mr. Eisiminger is President, Chief Executive Officer, and on the Board of Directors. Tom joined Regenesis Biomedical in 2006 after a short tenure with GlaxoSmithKline, and served in successive leadership roles culminating in his most recent position as Vice President of Sales. Tom served our country in the Army for 20+ years and is a decorated combat veteran. He held numerous leadership positions from platoon to battalion command. He managed the largest geographically dispersed Army Recruiting Battalion responsible for operations in SW Washington, Oregon, Northern California, Hawaii, Korea, Japan, Guam, American Samoa, Commonwealth of the Northern Marianas Islands, and the Freely Associated States of the Republic of the Marshall Island, Republic of Palau and the Federated States of Micronesia. He twice earned awards as top recruiting unit in the Army. Tom is a member of the Veterans of Foreign Wars, the American Legion, and the Disabled American Veterans. He is a veteran’s advocate and serves as President of the Veterans Medical Leadership Council (VMLC), a Phoenix based non-profit whose mission is to ensure quality medical & mental health care for Veterans and to encourage initiatives that honor the contributions made to the city, state & nation by Veterans and the men and women serving in the U.S. military. A former Board member of several veteran non-profits, he is also a member of the Arizona Veterans Hall of Fame Class of 2018. He currently serves on the Board of Directors of the American Diabetes Association (ADA) – Arizona, New Mexico, and Utah. He earned his B.S. from the U. S. Military Academy at West Point, his M.A. in National Security and Strategic Studies from the Naval War College, and his MBA from Marylhurst University in Portland, Oregon.
Randy Chavez – Vice-President, Regulatory Affairs and Quality Assurance
Mr. Chavez brings 20 years experience to the Regulatory and Quality role at Regenesis. He came aboard in 2008 with a successful track record of implementing Quality Management Systems and OUS applications for the EU, Canadian and Australian market approvals. His work at Regenesis has involved remediation and upgrade of the Quality Management System to FDA and ISO standards to bring the company forward from a specification developer to a manufacturer and release of a upgraded models of the Provant Therapy System. His key Regulatory projects at Regenesis involved multiple 510(k) submissions, reclassification of the Provant from a Pre-Amendments Class III device to a Class II device and CE Marking for expanded indications. Mr. Chavez has a B.S. in Chemical Engineering and an M.S. in Regulatory Science from Arizona State University.
Scott Robey – Vice-President, Marketing
Mr. Robey is a 30+ year marketing veteran. Prior to Regenesis he served as Senior Director of Marketing at Kinetic Concepts, Inc (KCI) for the V.A.C. Therapy brand during the time US product sales grew from about $70M in 2000 to about $1 billion by 2007. He has held marketing positions at Medtronic, Sulzer Carbomedics, and Burron Medical (B. Braun Medical, Inc). His responsibilities have included product management, new product development and commercialization, branding, clinical education programs, and key opinion leader and society relationship development. Mr. Robey has an M.S. in Management from Purdue University, and a B.S. in Biomedical Engineering from Louisiana Tech University.
Erica Tassone, PhD – Director, Life Sciences
Dr. Tassone is an expert in molecular biology and genomics, with extensive experience in data analysis, experimental design, and molecular techniques. She is a graduate of Arizona State University, where she earned her Ph.D. from the department of Life Sciences in Biology with a focus on Population Genetics. Dr. Tassone has over 15 years’ experience working in molecular biology and sequencing, and her work has contributed to over two dozen publications with a range of study organisms, including primates, crops, pests, and people. She has spoken at national conferences covering a range of her research topics. Utilizing cutting edge technology and hypothesis driven experimental design, she is passionate about using a collaborative approach to answer translational research questions for Regenesis patients.